Latest news with #VERVE-102
Yahoo
10-07-2025
- Business
- Yahoo
Verve Therapeutics, Inc. (VERV): A Bull Case Theory
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research's Substack by Stock Region. In this article, we will summarize the bulls' thesis on VERV. Verve Therapeutics, Inc.'s share was trading at $11.26 as of June 26th. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. Verve Therapeutics' stock surged an astounding 75% following Eli Lilly's $1.3 billion acquisition announcement, signaling a pivotal moment for the biotech space. At the heart of this excitement is VERVE-102, Verve's lead drug candidate targeting cardiovascular disease. The therapy, which aims to eliminate chronic disease management through gene editing, could mark a paradigm shift in how heart disease is treated. The FDA's Fast Track designation for VERVE-102 further underscores the drug's breakthrough potential and validates Verve's scientific approach. Eli Lilly's substantial bid is a clear vote of confidence, suggesting the pharma giant sees transformational value in Verve's pipeline. The acquisition not only provides financial validation but also shines a light on the evolving landscape of biotech, where high-impact innovation meets large-scale pharmaceutical backing. From a technical perspective, bullish momentum remains strong above $11.27, with caution advised if the stock dips below $10.95. Beyond the numbers, this deal exemplifies how cutting-edge therapies are attracting serious capital and reshaping the future of medicine. The excitement surrounding Verve's breakthrough technology and Eli Lilly's aggressive investment underscores the growing belief in gene editing as a frontier in healthcare. For investors, this move by Lilly isn't just about Verve—it reflects a broader confidence in biotech's ability to redefine chronic disease care. With VERVE-102 leading the charge and now bolstered by big pharma support, Verve appears well-positioned at the intersection of innovation and real-world impact, making this a landmark moment for the company and the sector at large. Previously we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by Two Natural Cap in June 2025, which highlighted the company's role in a groundbreaking base-editing therapy for a rare liver disorder. The company's stock price has appreciated approximately by 12.4% since our coverage. The thesis still stands as CRSP advances gene-editing leadership. Stock Region shares a similar outlook but emphasizes Verve's cardiovascular focus. VERV isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VERV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-06-2025
- Business
- Yahoo
BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside
-- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly's agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025. Lilly said on June 17 it would pay $10.50 in cash for each Verve share and up to another $3 through a contingent value right tied to a future Phase III trial of Verve's PCSK9-targeting therapy, valuing the deal at as much as $1.3 billion. BMO set its price target at $13.50, matching the total potential payout, and said it sees about a 70% chance that investors will receive the extra payment once the late-stage study begins, which the brokerage projects could happen by 2028. The brokerage said its downgrade reflects 'the definitive agreement to acquire VERV,' noting that Lilly's tender offer expires on July 23 and U.S. antitrust review is slated to end two days later. 'We expect a smooth deal closure by 3Q25 given LLY/VERV extensive relationship/partnership,' the analysts wrote. BMO said it will watch for 0.7 mg/kg dose data from an ongoing Phase Ib test of lead drug VERVE-102, where it models a 61–65% reduction in LDL cholesterol. Still, with Verve's trading at $11.25 in Friday premarket trading, already above Lilly's upfront offer, the brokerage sees little near-term upside. Verve's stock has more than doubled since Lilly announced the takeover, while Lilly's shares have dipped slightly. BMO added that the value of the CVR 'captures sufficient' risk around whether Verve can advance multiple late-stage trials and that the deal provides investors with a clearer timetable for any additional returns beyond the cash component. Related articles BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside Piper makes Meta its top large-cap pick, lifts price view on AI-driven ad gains BofA cuts Molson Coors rating as U.S. beer slide deepens
Canada News.Net
20-06-2025
- Business
- Canada News.Net
Eli Lilly bets on Verve, cholesterol gene therapy in $1.3 billion deal
INDIANAPOLIS, Indiana: Eli Lilly is making a bold play in cardiovascular gene therapy, announcing plans to acquire its partner Verve Therapeutics for up to US$1.3 billion as it expands beyond its blockbuster diabetes and weight-loss drugs. The move signals the pharmaceutical giant's more profound commitment to developing one-time gene-editing treatments for heart disease — specifically targeting high cholesterol — through technologies like base editing. Under the agreement announced this week, Lilly will pay $10.5 per share for Verve, a 67.5 percent premium over the biotech's previous closing price. Verve shares surged 75 percent to $11.02 in early trading. The Financial Times was the first to report that the deal was in the works. The transaction includes nearly $1 billion in upfront payments and up to $300 million in milestone-based payouts. The companies had already been collaborating on experimental therapies that use gene editing to reduce cholesterol in patients with a history of cardiovascular issues — a significant focus area for Lilly as it seeks long-term growth. Verve's leading candidate, VERVE-102, is in early trials and targets the PCSK9 gene, which is linked to cholesterol regulation. The therapy, based on base editing, aims to make a one-time change to a patient's DNA and is expected to be launched later this decade. "We are skeptical about the true market need of additional genetic medicines in these indications," said BMO Capital Markets analyst Evan Seigerman ahead of the announcement, citing competition from other cholesterol-lowering drugs. Still, industry observers said the deal is a significant boost for Verve and for the broader gene-editing field, which has struggled to attract investor enthusiasm recently. "This keeps Lilly focused within the cardiometabolic space," said Kevin Gade, COO at Bahl & Gaynor, referring to Lilly's core strength areas like diabetes and weight loss. Its therapies Mounjaro and Zepbound are projected to bring in over $30 billion this year, according to LSEG. Lilly has inked multiple partnerships with gene-editing firms in recent years, but this latest buyout is one of its boldest bets yet in the field.
Yahoo
18-06-2025
- Business
- Yahoo
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B
Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential payments dependent on certain trial milestones. Verve has an early stage clinical trial of a treatment to lower cholesterol and treat cardiovascular of Verve Therapeutics (VERV) skyrocketed 75% Tuesday morning after Eli Lilly (LLY) announced that it would acquire the gene-editing startup for about $1.3 billion. Eli Lilly said it will pay $10.50 per share to Verve shareholders initially, with a $3-per-share contingent value right (CVR) potentially paid out if Verve treats at least one patient with gene-editing medicine VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a Phase 3 clinical trial within a decade of the deal's closing or termination of the CVR. The transaction is expected to close in the third quarter this year. VERVE-102 currently "is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration," Lilly said. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," Verve CEO Dr. Sekar Kathiresan said. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly." The Financial Times reported late Monday that the companies were close to a deal. Eli Lilly shares, which entered Tuesday up roughly 5% this year, were down less than 1% in recent trading. With today's sharp gains, Verve stock has nearly doubled in 2025. UPDATE—This article has been updated with the latest share price information. Read the original article on Investopedia
Yahoo
17-06-2025
- Business
- Yahoo
Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion
Eli Lilly (NYSE:LLY) is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right worth up to $3.00 more. Under the agreement, Lilly will launch a tender offer for Verve's outstanding stock at $10.50 a shareabout a 113% premium to Verve's 30-day VWAP as of June 16totaling roughly $1 billion at closing. Each share also carries a non-tradeable contingent value right that can deliver up to $3.00 more, bringing the total possible consideration to $13.50 per share (?$1.3 billion). Warning! GuruFocus has detected 3 Warning Signs with VERV. Verve's shares jumped about 78% in premarket trading on the news this morning. Boston-based Verve is developing single-course in vivo base editing therapies targeting liver genes implicated in atherosclerotic cardiovascular disease. Its lead candidate, VERVE-102, is in Phase 1b trials for familial hypercholesterolemia and premature coronary artery disease and carries FDA Fast Track designation. This acquisition plugs Lilly directly into cutting-edge gene editing, supplementing its large cardiovascular franchise with a potential one-and-done therapeutic approach. A successful base editing therapy could redefine how chronic heart disease is managedshifting care from lifelong regimens to single-treatment cures. Investors will be watching regulatory progress for VERVE-102, data from the ongoing Phase 1b study and how Lilly integrates Verve's specialized R&D into its broader pipeline. Early clinical readouts and FDA feedback will be key catalysts for realizing the acquisition's full value. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
